We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Serum Bone Alkaline Phosphatase Activity Methods Compared

By LabMedica International staff writers
Posted on 02 Aug 2016
Print article
Image: The Access 2 immunoassay system (Photo courtesy of Beckman Coulter).
Image: The Access 2 immunoassay system (Photo courtesy of Beckman Coulter).
Serum bone alkaline phosphatase is a marker of bone formation and metabolism, however, existing methods for measuring it have their limitations and their accuracy has not been determined.

Alkaline phosphatase (ALP) isozymes have been used as biomarkers for liver and bone disease in the clinic and the measurement of ALP isozymes activity in serum has a high clinical value in the differential diagnosis and analysis of some diseases.

Scientists at the Hamamatsu University School of Medicine (Japan) measured serum bone ALP activity in 127 patients with liver disease using two methods, electrophoresis and chemiluminescent enzyme immunoassay (CLEIA). Of these, 52 patients had primary biliary cirrhosis, eight were affected by cholestatic cirrhosis, 13 had cholestatic hepatic disorder, and the rest were diagnosed with other liver diseases.

The team used for the analysis of ALP isozymes, electrophoresis agarose gels Quick Gel ALP with Quick ALP reagent (Helena Labs, Beaumont, TX, USA). In order to separate liver- and bone-type ALP completely, samples were pretreated with neuraminidase. In addition, samples were pretreated with protease to separate bone- and intestinal-type. Bands were scanned by densitometry at a wavelength of 570 nm. ALP isozyme activity was expressed in U/L and as a percentage of total ALP activity.

A one-step immunoenzymatic assay was used in this study. An automated chemiluminescence enzyme immunoassay device, known as an Access Immunoanalyzer (Beckman Coulter, Brea, CA, USA), and a special bone-type ALP (BAP) kit (also from Beckman Coulter) were used. Basic biochemical examinations of serum samples, using a chemistry analyzer (Labospect 008; Hitachi Ltd, Tokyo, Japan), were undertaken.

The investigators found that when ALP3 isozyme values were high ((%; bone-type isozyme activity as a percentage of total ALP activity), the two methods showed good correlation. However, with a decrease in ALP3 percentage levels, the correlation coefficient (R) also decreased. Starting with ALP3 (%) of less than 23%, R values markedly decreased to less than 0.5. Five outliers displayed low ALP3 (%) activity levels. Furthermore, in regard to genders, there were significant differences in total cholesterol (TC), γ-glutamyltransferase (γ-GTP), ALP and ALP3 (%) levels.

The authors concluded that the study suggests that for whole and bone-type ALP predominating (ALP2% equal to or less than ALP3%) samples, electrophoresis and CLEIA methods show good correlation. However, the accuracy of electrophoresis needs to be evaluated with further when patient samples under certain conditions. The study was published on June 9, 2016, in the journal Clinica Chimica Acta.

Related Links:
Hamamatsu University School of Medicine
Helena Labs
Beckman Coulter
Hitachi
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.